leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma says its SHIR Beauty & Science CBD Derma Cosmetics greenlit to be marketed in European Union

The company said its products have “successfully" passed safety assessment in accordance with European Union cosmetic regulation No 1223/2009

InnoCan Pharma - Innocan Pharma says its SHIR Beauty & Science CBD Derma Cosmetics get greenlight to be marketed in European Union
CEO Iris Bincovich said compliance with EU regulation is "a major milestone" for the company, after receiving technical validation from the FDA to market its Relief & Go Pain Relief spray in the US

Innocan Pharma Corporation (CSE:INNO) announced Thursday that its SHIR CBD Derma Cosmetic product line has received the greenlight to be marketed in the European Union.

The company said its products had “successfully" passed safety assessment in accordance with European Union cosmetic regulation No 1223/2009, and also received a EU Cosmetic Product Safety Report for marketing in the European Union.

According to Innocan, SHIR skincare products combine the benefits of CBD with the most effective ingredients in an “innovative formula” to deliver “visible results.” The SHIR Beauty & science products that are approved for marketing in the Europe include a SHIR CBD+ ANTI-AGING Beauty Sleeping Mask, SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, and SHIR CBD+ ANTI-AGING Facial Serum.

READ: Innocan Pharma says over-the-counter Relief & Go Pain Relief spray wins FDA approval to commence marketing

"As a pharma company, Innocan is committed to creating premium products that meet the highest quality standards to provide consumer confidence," Innocan co-founder and CEO Iris Bincovich said in a statement.

"Compliance with EU regulation is a major milestone for us, following the receipt of technical validation from the FDA for the marketing in the US of our over-the-counter Relief & Go Pain Relief spray, a few weeks ago,” she added.

Bincovich emphasized that the “next step” for the company is to get to work on “various distribution platforms” to deliver the SHIR CBD cosmetic line across the European Union and other markets where it is legally permitted.

The company, through its wholly-owned subsidiary Innocan Pharma Ltd in Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients.

Innocan and Ramot at Tel Aviv University are collaborating on the development of a new exosome-based technology that targets both central nervous system indications and the coronavirus (COVID-19).

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: InnoCan Pharma

Price: 0.3 CAD

CSE:INNO
Market: CSE
Market Cap: $52.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma received U.S. FDA approval for their over the counter CBD...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection. Bincovich talks about the collection and when they would...

on 07/20/2020

2 min read